Literature DB >> 6605119

Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis.

M R Laurent, G S Panayi.   

Abstract

The erythrocyte sedimentation rate (ESR) and the serum acute-phase proteins (APP), C-reactive protein (CRP), fibrinogen, 9th component of complement (C9), and alpha, antitrypsin were measured on 231 occasions in 80 patients with ankylosing spondylitis and compared with those in 30 controls. APP levels did not correlate with clinical assessment of disease activity. However, there were significant correlations between CRP, C9, and fibrinogen (p = less than 0.01), suggesting that these APP may be more reliable indicators of disease activity. The mean values of the APP in those patients with a peripheral arthritis were significantly higher than in those with pelvospondylitis alone for ESR (p less than 0.01), CRP (p less than 0.01), and fibrinogen (p less than 0.05). The only significant difference between those patients with an iritis and those with only pelvospondylitis was an elevated CRP in the iritis group (p less than 0.01). This suggests that a peripheral arthritis is the most important cause of an elevated ESR or APP in ankylosing spondylitis. Serum immunoglobulins were also measured and they showed a significant elevation of IgA in all 3 patients groups, there being no difference between each group. Serum IgG was raised only in those patients with an iritis or peripheral arthritis, the IgM levels being within the normal range for all patient groups.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605119      PMCID: PMC1001289          DOI: 10.1136/ard.42.5.524

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis.

Authors:  T D Kinsella; L Espinoza; F B Vasey
Journal:  J Rheumatol       Date:  1975-09       Impact factor: 4.666

2.  The assessment of rheumatoid arthritis. A study based on measurements of the serum acute-phase reactants.

Authors:  B McConkey; R A Crockson; A P Crockson
Journal:  Q J Med       Date:  1972-04

3.  The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis.

Authors:  B McConkey; R A Crockson; A P Crockson; A R Wilkinson
Journal:  Q J Med       Date:  1973-10

4.  Granuloma weight and the alpha 1-acute phase protein response in rats injected with turpentine.

Authors:  D A Darcy
Journal:  Br J Exp Pathol       Date:  1970-02

5.  Serum protein changes during the acute phase reaction.

Authors:  M Werner
Journal:  Clin Chim Acta       Date:  1969-08       Impact factor: 3.786

6.  Synthesis of the ninth component of guinea pig complement (C9) in response to experimentally induced inflammation.

Authors:  M Takahashi; S Kawachi-Takahashi; K Yamamoto
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

7.  Serum immunoglobulins in ankylosing spondylitis.

Authors:  M J Kendall; M Farr; N Williamson
Journal:  Br Med J       Date:  1973-07-21

8.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

9.  Serum IgG, IgM, and IgA levels in ankylosing spondylitis.

Authors:  E M Veys; M van Leare
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

10.  Determination of serum C9 level by immunodiffusion. Elevation in patients with infectious or allergic skin diseases.

Authors:  S Kawachi-Takahashi; K Tanaka; M Takahashi; T Kawashima; K Shimada
Journal:  Int Arch Allergy Appl Immunol       Date:  1975
View more
  18 in total

1.  Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis.

Authors:  H Hocini; S Iscaki; C Benlahrache; L Vitalis; X Chevalier; B Larget-Piet; J P Bouvet
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Red blood cell distribution width: a potential maker estimating disease activity of ankylosing spondylitis.

Authors:  You-Fan Peng; Qiong Zhang; Ling Cao; Yang Liu; Dan Chen; Yu-Kun Sun; Zhao-Xia Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Spondyloarthropathies and IgA deficiency.

Authors:  H G Taylor; P T Dawes
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

4.  Reference distributions for immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature.

Authors:  R F Ritchie; G E Palomaki; L M Neveux; O Navolotskaia
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 5.  Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors:  Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2020-07-13       Impact factor: 20.543

6.  Relationship between the severity of enthesitis and clinical and laboratory parameters in patients with ankylosing spondylitis.

Authors:  Taciser Kaya; Serpil Bal; Rezzan Gunaydin
Journal:  Rheumatol Int       Date:  2006-09-22       Impact factor: 2.631

7.  Serum and secretory IgA immune response to Klebsiella pneumoniae in ankylosing spondylitis.

Authors:  A K Trull; G S Panayi
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

8.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

9.  Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis.

Authors:  K M Sanders; A Hertzman; M R Escobar; B H Littman
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

10.  Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.

Authors:  R Cooper; S M Fraser; R D Sturrock; C G Gemmell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.